{"public_id":"cl_c04b5039f7f9a7950a0463d00ffc6ca1","status":"active","superseded_by_public_id":null,"corpus_id":240541392,"text":"Most additional trials enabled by comprehensive genomic profiling were phase 1 or phase 2 trials and involved metastatic disease.","confidence":0.94,"paper":{"corpus_id":240541392,"title":"Improvements in access to cancer clinical trials facilitated by comprehensive genomic profiling in non-small cell lung cancer.","url":"https://sah.borca.ai/papers/240541392"},"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.94,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["system","user_agent"],"verifier_class_counts":{"system":1,"user_agent":1},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"mixed","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_74dbd012487ad3fd1f0058e37cf1cb3b","name":"metastatic disease","description":"Disease severity category used to characterize additional clinical trials in the abstract.","types":["disease setting"],"url":"https://sah.borca.ai/concepts/co_74dbd012487ad3fd1f0058e37cf1cb3b"},{"public_id":"co_99cd3c487141127d1a76a166f7061b44","name":"phase 1 or 2","description":"Early clinical trial phases used to characterize most of the additional trials.","types":["trial phase"],"url":"https://sah.borca.ai/concepts/co_99cd3c487141127d1a76a166f7061b44"},{"public_id":"co_f80408534c2a09fa76f93907b24ab6f1","name":"additional clinical trials","description":"Trials potentially available to patients because comprehensive genomic profiling detects markers beyond the comparator panel.","types":["trial outcome"],"url":"https://sah.borca.ai/concepts/co_f80408534c2a09fa76f93907b24ab6f1"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_c04b5039f7f9a7950a0463d00ffc6ca1"}